Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-1-23
pubmed:abstractText
Transmissible spongiform encephalopathies are associated with the conformational conversion of the prion protein from the cellular form (PrP(C)) to the scrapie form. This process could be disrupted by stabilizing the PrP(C) conformation, using a specific ligand identified as a chemical chaperone. To discover such compounds, we employed an in silico screen that was based on the nuclear magnetic resonance structure of PrP(C). In combination, we performed ex vivo screening using the Fukuoka-1 strain-infected neuronal mouse cell line at a compound concentration of 10 microM and surface plasmon resonance. Initially, we selected 590 compounds according to the calculated docked energy and finally discovered 24 efficient antiprion compounds, whose chemical structures are quite diverse. Surface plasmon resonance studies showed that the binding affinities of compounds for PrP(C) roughly correlated with the compounds' antiprion activities, indicating that the identification of chemical chaperones that bind to the PrP(C) structure and stabilize it is one efficient strategy for antiprion drug discovery. However, some compounds possessed antiprion activities with low affinities for PrP(C), indicating a mechanism involving additional modulation factors. We classified the compounds roughly into five categories: (i) binding and effective, (ii) low binding and effective, (iii) binding and not effective, (iv) low binding and not effective, and (v) acceleration. In conclusion, we found a spectrum of compounds, many of which are able to modulate the pathogenic conversion reaction. The appropriate categorization of these diverse compounds would facilitate antiprion drug discovery and help to elucidate the pathogenic conversion mechanism.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-10590120, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-10595502, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-10708429, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-10775631, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-11095725, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-11504948, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-12121656, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-12140563, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-12857915, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-12904059, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-12970413, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-14676316, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-1509259, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-15211508, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-16118363, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-16242887, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-16981681, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-17004707, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-17305326, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-17616582, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-17643109, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-7553876, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-7909169, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-9280297, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-9294164, http://linkedlifedata.com/resource/pubmed/commentcorrection/19015328-9811807
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1098-6596
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
765-71
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
pubmed:affiliation
Center for Emerging Infectious Diseases, Gifu University, Yanagido, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't